Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Neuroendocrine Tumors 4Sarcoma 2Neoplasms 2Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Lymphoma 1Cholangiocarcinoma 1Carcinoid Tumor 1Biliary Tract Neoplasms 1Advanced Solid Tumors 1

Interventions

Irinotecan 13Cyclophosphamide 11Vincristine 10Filgrastim 10Radiotherapy 9Ifosfamide 9Doxorubicin 9Dactinomycin 7Melphalan 6Granulocyte Colony-Stimulating Factor 6Etoposide 6cixutumumab 5Sirolimus 5Peripheral Blood Stem Cell Transplantation 5pegfilgrastim 4Topotecan 4Temozolomide 4Radiation 4Gemcitabine 4Busulfan 4temsirolimus 3sargramostim 3Granulocyte-Macrophage Colony-Stimulating Factor 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3trioctyl phosphine oxide 2regorafenib 2olaparib 2etoposide phosphate 2eribulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Rhabdomyosarcoma × surufatinib × Clear all
NCT05093322 2024-06-07

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Hutchmed

Phase 1/2 Completed
13 enrolled 17 charts
LymphoidSarcoma

Lymphoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡